Filing Flows › Accelerant (ARX) › Stock forecast & fair value
Accelerant (ARX) stock forecast and fair value
Accelerant (ARX) trades at $19.89. The analysts' price target is $20.25 (+2%). Across 4 valuation methods the middle fair value is $20.25 (+2%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Residual income | −$2.95 | −$2.98 | −$3.02 | -115% |
| Analysts' price targets | $20.25 | $20.25 | $20.25 | +2% |
| Stage-weighted value (financial (bank / insurer)) | −$3.02 | −$2.98 | −$2.95 | -115% |
| Combined forecast (3 months) | $16.29 | $20.68 | $25.62 | +4% |
Accelerant's latest quarter
Accelerant, Q2 2026: revenue $357M (+63% year over year), operating margin 24.5%, net earnings $78.7M, operating cash flow −$68.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ARX stock?
The analysts' 12-month target is $20.25, +2% from $19.89. The average rating is none.
What is Accelerant's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$2.98 and $20.68, with a middle value of $20.25 against a price of $19.89. Each method's assumptions are on the page.
Does Accelerant usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is ARX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.